Latest Breaking News On - சர்வதேச சிம்போசியம் ஆன் குழந்தை நரம்பியல் - Page 1 : comparemela.com

Week Ahead In Pharma: FDA Decision, Review Of COVID-19 Vaccine, Data Readouts (Moderna, BCRX, ARVN.) THOUSAND OAKS (dpa-AFX) - The week that just passed by saw a couple of stocks belonging to the healthcare sector record triple-digit gains and nearly a dozen managing to log gains in excess of 50 percent, thanks to positive clinical trial readouts. Greenwich LifeSciences Inc. (GLSI), which closed out the week at $56, delivering over 890%, was the top gainer of the week, following promising five year-data related to its drug candidate GP2 in a phase II clinical trial in HER2 positive women with operable breast cancer. Curis Inc. (CRIS) closed the week at $7.89, recording a weekly gain of nearly 320%, on the back of positive preliminary data from its ongoing phase I study of CA-4948 monotherapy in patients with relapsed or refractory Acute Myeloid Leukemia and Myelodysplastic Syndromes.

United statesHong kongAbbvie lupronMyovant relugolixRoche rituxanCellectar biosciencesAstrazeneca zoladexGossamer bio incArvinas incZai labAdvisory committeeCellectar biosciences incCuris incGreenwich lifesciences incTherapeutics incModerna inc